[HTML][HTML] Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.

R Gilson, D Nugent, K Bennett, CJ Doré… - Health Technology …, 2020 - ncbi.nlm.nih.gov
BACKGROUND The comparative efficacy, and cost-effectiveness, of imiquimod or
podophyllotoxin cream, either alone or in combination with the quadrivalent HPV vaccine …

Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with …

ML Murray, J Meadows, CJ Doré, AJ Copas… - BMC medical research …, 2018 - Springer
Background Anogenital warts are the second most common sexually transmitted infection
diagnosed in sexual health services in England. About 90% of genital warts are caused by …

Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts

P Komericki, M Akkilic-Materna… - Sexually transmitted …, 2011 - journals.lww.com
Background: Anogenital warts are a common sexually transmitted disease caused by
human papillomaviruses. Despite the fact, that imiquimod and podophyllotoxin represent …

Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts

SK Tyring, I Arany, MA Stanley, MH Stoler… - Primary Care Update for …, 1998 - Elsevier
Objective: The objective of this randomized, double-blind, placebo-controlled trial was to
evaluate the mechanism of action of imiquimod cream in the treatment of anogenital warts …

New approach to managing genital warts

CC Lopaschuk - Canadian Family Physician, 2013 - cfp.ca
Objective To summarize and determine the appropriate use for the new and old
management tools for genital warts. Sources of information The following databases were …

The cost-effectiveness of patient-applied treatments for anogenital warts

P Williams, G von Krogh - International journal of STD & …, 2003 - journals.sagepub.com
A model was developed to estimate the cost-effectiveness of podophyllotoxin and imiquimod
for self-treatment of anogenital warts. The effectiveness endpoint was sustained clearance …

Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo‐controlled studies

DA Baker, DG Ferris, MG Martens… - … in obstetrics and …, 2011 - Wiley Online Library
Objective. To evaluate if new imiquimod formulations using a shorter treatment duration are
safe and efficacious to treat anogenital warts. Methods. In two studies 534 women≥ 12 …

The importance of patient and healthcare provider perceptions in the evaluation of imiquimod and other prior treatments for anogenital warts

AL Nelson - International journal of STD & AIDS, 2002 - journals.sagepub.com
The experience and satisfaction of healthcare providers and patients were assessed for
various treatment options for anogenital warts. Patients were asked about their immediate …

Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis

RN Werner, L Westfechtel, C Dressler… - Sexually Transmitted …, 2017 - sti.bmj.com
Background Anogenital warts (AGWs, condylomata acuminata) are among the most
common STIs and may severely impact quality of life (QoL). Available treatment options are …

Percutaneous penetration of Aldara™ cream, 5% during the topical treatment of genital and perianal warts

ML Owens, WE Bridson, SL Smith, JA Myers… - Primary Care Update for …, 1998 - Elsevier
Objective: The objective of this single-center, open-label trial was to evaluate the
percutaneous penetration of Aldara™(imiquimod) cream, 5% when applied topically to …